A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis

NACompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

January 9, 2020

Study Completion Date

April 24, 2024

Conditions
Coronary In-stent Restenosis
Interventions
DEVICE

Dissolve™

Dissolve™ are to be used in the trial

DEVICE

SeQuent®Please

SeQuent®Please are to be used in the trial

Trial Locations (15)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing

Beijing Hospital, Beijing

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

Peking Union Medical College Hospital, Beijing

Peking University People's Hospital, Capital Medical University, Beijing

Xiangya Hospital of Central South University, Changsha

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital of Dalian Medical University, Dalian

The Second Affiliated Hospital of Dalian Medical University, Dalian

General Hospital of Daqing Oil Field, Daqing

Sir Run Run Shaw Hospital, Zhejiang University School of medicine, Hangzhou

The First Affiliated Hospital of Zhengzhou University, Hangzhou

Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan

General Hospital of Ningxia Medical University, Yinchuan

All Listed Sponsors
collaborator

Core Medical (Beijing) Co., Ltd.

OTHER

lead

DK Medical Technology (Suzhou) Co., Ltd.

INDUSTRY

NCT03373695 - A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis | Biotech Hunter | Biotech Hunter